BioClever 2005 S.L.
10
3
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.0%
2 terminated/withdrawn out of 10 trials
33.3%
-53.2% vs industry average
50%
5 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
AEF0217 in Participants With Down Syndrome
Role: collaborator
Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL
Role: collaborator
Efficacy and Safety Evaluation for the Treatment of Allergy Against Mites
Role: collaborator
Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia
Role: collaborator
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Role: collaborator
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
Role: collaborator
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
Role: collaborator
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
Role: collaborator
Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection
Role: collaborator
Direct Transfer to an Endovascular Center Compared to Transfer to the Closest Stroke Center in Acute Stroke Patients With Suspected Large Vessel Occlusion
Role: collaborator
All 10 trials loaded